This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In a recent issue of the ARCHIVES,¹ we reported lower fracture risk among women taking 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) for hypercholesterolemia. The research was prompted by the finding that statins increase bone morphogenetic protein-2, leading to osteoblast differentiation and bone formation.² The substantial 60% reduction in fracture risk we reported persisted after adjusting for potential confounders and was greater than expected from increases observed in bone mineral density alone.

Recent data from Britain³ and Australia⁴ support a role for statins in preventing age-related macular degeneration. The authors suggest that statins might prevent the accumulation of basal linear deposit in the Bruch membrane, protect the retina from oxidative damage, and maintain a competent vascular supply to the macula.³ Statins have also been reported to protect against dementia, which may be explained, at least in part, by the protective effect of statins on vascular disorders.⁵ Given that poor vision and . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Commentary: Statins and fracture risk--unresolved questions.
Meier
Int J Epidemiol 2006;35:1308-1309.
FULL TEXT